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Infection of the stomach with Helicobacter pylori is an important risk factor for gastritis, peptic ulcer, and gastric carcinoma.
Although it has been well established that persistent colonization by H. pylori is associated with adaptive Th1 responses, the
innate immune responses leading to these Th1 responses are poorly deﬁned. Recent studies have shown that the activation
of nucleotide-binding oligomerization domain 1 (NOD1) in gastric epithelial cells plays an important role in innate immune
responses against H. pylori. The detection of H. pylori-derived ligands by cytosolic NOD1 induces several host defense factors,
including antimicrobial peptides, cytokines, and chemokines. In this paper, we review the molecular mechanisms by which NOD1
contributes to mucosal host defense against H. pylori infection of the stomach.
1.Introduction
Helicobacter pylori is a microaerophilic, gram-negative bac-
teriumthatcolonizeshumangastricmucosa[1,2].Although
most individuals with a chronic gastric infection of H. pylori
are asymptomatic, this bacterium causes peptic ulcer or
gastric cancer in a subpopulation of susceptible hosts [1, 2].
The development of gastric disease associated with H. pylori
infection is determined by the interplay between bacterial
virulence factors and host immune responses. The cag-
pathogenicity island (PAI) is one of the most important
virulence factors of H. pylori. Infection with strains of
H. pylori carrying cag-PAI is associated with severe gastric
disease, including gastric cancer [3].
Chronic infection with H. pylori is characterized by a
strong T helper type 1 (Th1) response in the gastric mucosa
[4, 5]. Th1 cells produce IFN-γ-mediated mucosal host
defense against this organism as shown by the fact that IFN-
γ-deﬁcient mice fail to eradicate the bacteria from their
stomachs upon oral administration of this organism [6].
Although it is well established that the gastric mucosa of
patients with H. pylori infection is characterized by adaptive
Th1 responses, the innate immune responses leading to such
Th1 responses are poorly understood. Pattern recognition
molecules particularly Toll-like receptors (TLRs) play a cru-
cial role in host defense against mucosal pathogens. TLRs are
evolutionarily conserved receptors, which recognize micro-
bial antigens and contribute to host defense by producing
proinﬂammatory cytokines and antimicrobial peptides [7].
The activation of TLRs in antigen-presenting cells (APCs)
by TLR ligands associated with H. pylori has in fact been
shown to be involved in the generation of protective Th1
responses against H. pylori [8]. In addition, the neutrophil-
activating protein of H. pylori induces Th1 responses via
TLR2-mediated IL-12 secretion in APCs [9]. Thus, it is clear
that the detection of H. pylori-associated antigens by APCs
expressing TLRs plays a role in the induction of protective
anti-H. pylori Th1 responses.2 International Journal of Inﬂammation
Given the fact that most gastric APCs are localized in the
submucosal areas and that H. pylori adheres to the luminal
surface of the epithelium [10], it is likely that innate immune
responses by gastric epithelial cells (ECs) directly activated
by the organism are involved in the immunopathogenesis of
H. pylori-associated gastric diseases. TLR signaling may be
involved in the development of H. pylori-associated gastric
disease since patients with gastric adenocarcinoma are more
likely to carry the TLR4 polymorphisms [11]. However, on
the other hand, TLR signaling may not necessarily play a
major role since gastric ECs have been shown to be hypo-
responsive to TLR ligands [12]. Another possibility is that
epithelial cell signaling occurs through Nucleotide-binding
oligomerization domain, Leucine-rich Repeat-containing
(NLR) proteins, that is, a rapidly emerging family of innate
immune regulatory molecules that function much like TLRs
b u tw i t hd i ﬀerent signaling mechanisms [13]. Nucleotide-
binding oligomerization domain 1 (NOD1) is of particular
relevance in this context since NOD1, a member of the
NLR family proteins, recognizes small peptides derived from
peptidoglycan (PGN), a component of bacterial cell walls,
and is expressed in APCs and gastric ECs [14]. In addition,
Viala et al. has shown that eradication of H. pylori requires
the sensing of PGN by cytosolic NOD1 expressed in gastric
ECs [15]. Since this latter discovery, several mechanisms
regarding NOD1-mediated mucosal host defense against
H. pylori have been proposed. In this paper, we focus on
these mechanisms with the aim of explaining just how
NOD1 signaling contributes to gastric inﬂammation and
host defense against H. pylori.
2. Expression of NOD1
NOD1 consists of a C-terminal LRR (Leucine-rich region), a
central NOD, and an N-terminal CARD (caspase-activating
domain) domain [14]. Whereas TLRs are associated with the
plasmamembraneorendosomalvesicles,NOD1isexpressed
in the cytosol [14]. NOD1 is mainly expressed by cells—
APCs and ECs—that are exposed to microorganisms [14].
Importantly, mostgastrointestinalcelllinesandprimary ECs
express NOD1 [15, 16].
NOD1 expression is regulated by proinﬂammatory
cytokines. IFN-γ activates the promoter of NOD1 via
nuclear translocation of IFN-regulatory factor 1 (IRF1)
to up-regulate the expression of NOD1 in intestinal ECs
whereas NF-κB activation by TNF does not alter the NOD1
expression in these cells [16, 17].
3.SignalingPathwaysof NOD1
It is now established that NOD1 senses a small molecule
derived from bacterial cell wall PGN. A minimum motif of
NOD1 ligand is γ-D-glutamyl-meso-diaminopimelic acid—
called iE-DAP. PGN derived from most gram-positive bacte-
ria lacks iE-DAP. In contrast, PGN derived from most gram-
negative bacteria contains iE-DAP. Thus, NOD1 functions as
a sensor for gram-negative bacteria. In support of this idea,
it has been shown that NOD1 participates in host defense
against mucosal infection with gram-negative bacteria such
asShigella,Escherichiacoli,andH.pylori[18,19]althoughno
functional mutations have been found to be associated with
upper gastrointestinal diseases caused by chronic infection
with H. pylori [20].
One pathway of NOD1 signaling relates to its ability to
activate NF-κB and MAP kinases [14]. Such signaling is ini-
tiated by the detection of NOD1 ligands by the LRR domain
of NOD1 which is then followed by the recruitment of a
downstream eﬀector molecule, RICK [14]. RICK is a CARD-
containing serine/threonine kinase that physically binds to
NOD1 through a CARD-CARD interaction [14]. RICK then
undergoesK63-linkedubiquitinationandacquirestheability
torecruitandactivateTGF-β-activatedkinase1(TAK1)[21];
the latter, in turn, initiates activation of NF-κB subunits
through phosphorylation and K48-linked ubiquitination of
IκBα. This sequence of events suggests that the binding of
RICK to NOD1 and its K63-linked polyubiquitination is
a key step in the NOD1-mediated signaling cascade with
respect to responses involving NF-κB and MAP kinases and,
as we shall see to other responses as well. This supposition is
fully supported by the fact that NOD1 responses are severely
curtailed in RICK-deﬁcient cells [14].
The above NOD1 signaling pathway emphasizes the
importance of ubiquitination in the signaling cascade. On
the one hand, conjugation of K48-linked polyubiquitin
chains with the inhibitory protein IκBα leads to proteasomal
degradation of IκBα and the nuclear translocation of NF-κB
subunits such as p65 and p50. On the other hand, conjuga-
tionofK63-linkedpolyubiquitinchainstoRICK,ratherthan
causing RICK degradation leads to the creation of a scaﬀold
that enables recruitment of signaling components, such as
TAK1. The ligases that conjugate K63-linked polyubiquitin
chains to RICK have recently been identiﬁed as the cellular
inhibitors of apoptosis proteins (cIAP), cIAP1, and cIAP2
[22]. These proteins bind to NOD1 following the latters’
activation by its ligands and have C-terminal RING ﬁnger
domains with E3 ligase activity which then K63-ubiquitinate
the RICK (Figure 1).
As shown in recent studies [19, 23, 24], the stimulation
of ECs with NOD1 ligands leads to robust production of
proinﬂammatory chemokines. We conﬁrmed and extended
these ﬁndings with studies showing that such stimulation
induced Th1 chemokines (IFN-γ-induced protein of 10kDa,
IP-10) in gastrointestinal ECs including freshly isolated
primary ECs [17] both in the presence and absence of
IFN-γ. Initially, we and others attributed such induction
to a signaling pathway involving NF-κB, along the lines
described above. We noted, however, that the possible
involvement of NF-κB was based largely on signaling studies
utilizing transfected cells, in which NOD1 and/or an NF-
κB reporter gene were overexpressed, rather than on studies
employing cells expressing endogenous NOD1 stimulated
underphysiologicconditions.Thisintroducedthepossibility
that signaling pathways not involving NF-κB activation play
an important role in NOD1 induction of chemokines in
EC. In an extensive series of studies to investigate this
possibilitywefoundthatindeed,stimulationofECbyNOD1























Figure 1: Signaling pathways of NOD1. NOD1 activation induces an interaction between RICK and TRAF3 that results in the production
of IFN-β through activation of TBK1, IKKε, and IRF7. IFN-β production leads to production of IP-10 through transactivation of ISGF3
(Stat1-Stat2-IRF9 complex). NF-κB activation induced by NOD1 ligand leads to production of proinﬂammatory cytokines and chemokines
such as IL-8.
substantial NF-κB activation, but rather by the induction
of type I IFN which leads to IP-10 production by inducing
the IP-10 transcription complex, IFN-stimulated gene factor
3 (ISGF3) [17]. This comes about via a unique NOD1
signalingpathwaythatinvolvesinitialinteractionofactivated
RICK with TRAF3, followed by the activation of TANK-
binding kinase 1(TBK1) and IKKε and downstream IRF7 to
induce the production of IFN-β and, as mentioned ISGF3
(Figure 1). ISGF3, which is a heterotrimer composed of
Stat1, Stat2, and IRF9, not only acts as a transcription factor
for IP-10, but also for IRF7 which induces further IFN-β
production and further rounds of IP-10 production. Overall,
these studies showed that, at least with respect to ECs, NOD1
utilizes a signaling pathway more commonly identiﬁed with
cell signaling by viruses. Whether this signaling pathway
also deﬁnes NOD1 function in other kinds of cells, such as
macrophages, remains to be seen.
4. NOD1 Activation in
Helicobacter pylori Infection
The majority of patients with H. pylori-associated gastritis
have a higher NOD1 expression in gastric epithelial cells as
compared with controls or H. pylori-nonassociated gastritis
[20], which suggests the involvement of NOD1 signaling
in the development of human gastric inﬂammation. In
addition, animal studies demonstrate that a marked increase
of bacterial load in the stomachs of NOD1-deﬁcient mice
is observed upon acute infection with cag-PAI-positive, but
not cag-PAI-negative H. pylori as compared with NOD1-
intact mice [15, 17]. These data are related to the fact
that the detection of H. pylori-derived PGN by gastric
ECs is at least partially dependent on a functional type
IV secretion apparatus. Thus, as shown by Viala et al.,
H. pylori expressing functional cag-PAI eﬃciently delivered
radio-labeled PGN into the ECs, whereas H. pylori strain
251—harboring nonfunctional cag-PAI—failed to deliver
radio-labeled PGN [15]. In addition, these ﬁnding were
supported by studies showing that infection with H. pylori
induced IL-8 production by the gastric epithelial cell line,
AGS cells, in an NOD1/cag-PAI-dependent manner [25].
It should be noted, however, that Kaparakis et al. have
recently provided evidence for the existence of a cag-PAI-
independent mechanism for NOD1 activation [26]. These
authors puriﬁed outer membrane vesicles (OMVs) from cag-
PAI-positive and -negative bacteria. H. pylori-derived OMVs
containing numerous components of bacterial cell walls
including PGN, induced IL-8 production by AGS cells via an
NOD1-dependent and cag-PAI-independent fashion. OMVs
activate the cytosolic NOD1 of ECs through lipid rafts. In
addition, NOD1-deﬁcient mice exhibit defective innate and
adaptive immune responses to OMVs upon oral challenge
with OMVs [26]. Patients infected with strains lacking a
functional type IV secretion system still have inﬂammation
and Th1 responses. These data regarding NOD1 activa-
tion by OMVs may partially explain the mechanisms by
which NOD1-mediated Th1 responses against H. pylori
are induced in the absence of functional cag-PAI. On the
basis of this new data, further studies to determine the
conditions under which NOD1 activation upon H. pylori
infection requires functional type IV secretion apparatus are
warranted.4 International Journal of Inﬂammation
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Figure 2: Molecular mechanisms of NOD1-mediated mucosal host
defense against H. pylori. Infection of gastric epithelial cells with
H. pylori activates type I IFN signaling, which leads to the gener-
ation of protective Th1 responses. H. pylori infection induces hBD2




The generation of Th1 responses is required for mucosal
host defense against H. pylori infection [4, 6]. Although
the mechanism by which recognition of H. pylori-derived
PGN by cytosolic NOD1 activates the protective response
is not completely understood, two main models have been
proposed (Figure 2).
The ﬁrst model for the role of NOD1 activation in
H. pylori infection is based on the antimicrobial activity
of defensins produced by ECs. Grubman et al. showed
that H. pylori infection induces the production of human
β defensin 2 (hBD2) by AGS cells in an NOD1/cag-PAI-
dependent fashion [25]. Transfection of siRNA speciﬁc to
hBD2 impairs the killing of H. pylori, as shown by the
increased number of bacteria in culture supernatants from
AGS cells infected with cag-PAI-positive H. pylori. These
authors imply that NOD1 induction of hBD2 upon infection
with cag-PAI-positive H. pylori may be mediated by NF-
κB activation, but this is unclear since NF-κBa c t i v a t i o n
is assessed by reporter gene assays that may not reﬂect
endogenous NF-κB regulation [25]. Consistent with these
results,theexpressionofmurineβ-defensin4(anorthologue
of hBD2) is markedly reduced in the gastric mucosa of
NOD1-deﬁcient mice as compared with NOD1-intact mice
[27].ThesedataregardinghBD2inductionbyNOD1suggest
that NOD1 mediates host defense by the direct killing
of H. pylori through induction of hBD2. However, the
contribution of NOD1-induced defensins to the generation
of Th1 responses remains unknown.
The second model for the role of NOD1 activation in
H. pylori infection is based on the production of type I
IFN and activation of the ISGF3 signaling mediated by
NOD1. As we described in the previous section regarding
NOD1signalingpathways,thestimulationofgastrointestinal
ECs including primary cells with NOD1 ligands leads to a
robust production of IFN-β and the subsequent induction
of ISGF3 [17]. We therefore addressed the role of this new
signaling pathway in cag-PAI-positive H. pylori infection.
In in vitro studies we found that H. pylori infection of
AGS cells led to a massive increase of IFN-β and IP-
10 production, which was accompanied by the activation
of both Stat1 and Stat2, suggesting that cag+ H. pylori
organisms do indeed activate epithelial cells via the IFN-
β-ISGF3 pathway. Although H. pylori infection of the AGS
cells results in NF-κBa c t i v a t i o n , NF-κB activation induced
by H.pyloriinfectionisindependentofNOD1.Theinfection
of AGS cells in the presence of siRNA speciﬁc for NOD1
resulted in the impaired nuclear translocation of Stat1 and
production of IFN-β and IP-10, but unchanged nuclear
translocation of NF-κB subunit, p65 [17]. These results are
consistent with previous studies of Hirata et al. [28], who
showed that H. pylori organisms can activate NF-κBi n
epithelial cell lines through MyD88-dependent mechanisms,
but not NOD1-dependent mechanisms, and Viala et al. who
reported that primary gastric epithelial cells infected with
H. pylori produce chemokines in the absence of the nuclear
translocation of NF-κBp 6 5[ 15].
In further in vivo studies of NOD1 activation during
H. pylori infection we found a marked increase of bacterial
load in the stomachs of NOD1-deﬁcient mice as compared
with NOD1-intact mice. Furthermore, this was associated
with reduced production of type I IFN-ISGF3-associated
cytokines and chemokines such as IFN-β, IP-10, and IFN-γ
rather than NF-κB-associated cytokines such as TNF. Thus,
the activation of type I IFN and ISGF3 signaling via NOD1
is responsible for the generation of protective Th1 responses
against H. pylori [17]. This idea was conﬁrmed by the fact
that gene silencing of Stat1, a component of ISGF3, increases
the bacterial burden in the stomach of NOD1-intact mice
duetoimpairedTh1andtypeIIFNresponses.Therefore,itis
likelythatNOD1-mediatedtypeIIFNproductionandISGF3
activation provide protective Th1 responses upon infection
with cag-PAI-positive H. pylori.I ns u p p o r to ft h i sm o d e l ,I P -
10 expression is observed in the gastric mucosa of patients
with chronic H. pylori infection [5].
Recent studies addressing the role of NOD1 in mucosal
host defense against H. pylori have been focusing on
acute innate responses as assessed by cell-culture or animal
infection models. Thus, it is unclear how NOD1 activation
is involved in the development of various gastric diseases
associated with chronic H. pylori infection. In this regard,
IL-17 may play an important role in the chronic inﬂam-
matory responses to H. pylori infection as shown by the
overproduction of this cytokine in H. pylori-infected human
gastric mucosa [29]. In addition, vaccination of mice against
H. pylori results in eﬃcient eradication due to enhanced IL-
17 production in the gastric mucosa [30, 31]. It is possible
that NOD1 activation in response to H. pylori infection isInternational Journal of Inﬂammation 5
involved in the generation of gastric Th17 responses since
NOD1triggeringisrequiredtoinstructtheonsetofbothTh1
and Th17 responses [32].
6. Conclusions
Infection with cag-PAI-positive H. pylori leads to the acti-
vation of NOD1 in gastric ECs and to the induction of
several host defense factors including hBD2, IFN-β,a n dI P -
10,allofwhichregulatebacterialgrowth.Recentstudieshave
shownthatNOD1activationismediatedinECslargely,ifnot
entirely, by NOD1 induction of IFN-β and thus a signaling
pathway ordinarily activated by viral infection. This has
important implications for our views on how the mucosal
system utilizes innate immune mechanisms to deal with
chronic bacterial infections. Interestingly, proinﬂammatory
cytokine responses induced by TLR ligands are markedly
enhanced in the presence of NOD1 ligands. Therefore, it is
possible that the synergistic activation of NOD1 and TLRs in
gastric APCs also plays a role in mucosal host defense against
this organism. Thus, future studies addressing whether or
not NOD1 expression in APCs contributes to host defense




cIAPs: cellular inhibitor of apoptosis proteins
ECs: Epithelial cells
hBD2: human β defensin 2
IP-10: IFN-γ-induced protein of 10 kDa
IRF: IFN-regulatory factor
ISGF3: IFN-stimulated gene factor 3
LRR: Leucine-rich repeats
NLR: Nod-like receptor
NOD1: Nucleotide-binding oligomerization domain-1
OMVs: Outer membrane vesicles
PAI: Pathogenicity island
PGN: Peptidoglycan
TAK1: TGF-β-activated kinase 1
Th1: T helper type 1
TLRs: Toll-like receptors.
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